Condition: Relapsed or Refractory Multiple Myeloma (R/R MM)
Journal: Journal of experimental & clinical cancer research : CR
Treatment Used: B-Cell Maturation Antigen Combined with CD38 (BCMA-CD38) Bispecific Chimeric Antigen Receptor T (CAR-T) Cell Therapy
Number of Patients: 16
Published: January 04, 2022